Health Canada Safety Review Finds Link Between The Use Of Xeljanz And Xeljanz Xr (tofacitinib) And Increased Risk Of Serious Heart-related Issues And Cancer
Health Canada has determined that Xeljanz and Xeljanz XR (tofacitinib), prescription medications used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, are linked to an increased risk of serious heart problems and cancer. This safety review applies to patients across Canada who use these medications. The products are being recalled due to these safety concerns.
- Product
- Xeljanz and Xeljanz XR (tofacitinib), a prescription drug used to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.
- Reason
- Product safety
- Category
- consumer product recall
- Country
- Canada
- Agency
- HC-PRODUCTS
- Recall date
- 2022-01-12
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-PRODUCTS
Recall details on Nibble Recalls: https://trynibble.app/recalls/e10c8ef9-9d4e-4b79-89c1-8c1f166899ae